Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Dabigatran is superior to warfarin, but at what cost?

John Mandrola, MD
Meds
April 18, 2010
Share
Tweet
Share

Dysrhythmias like atrial fibrillation (AF), more often than not, require medical therapy.

The dreaded blood thinner, warfarin (Coumadin) comes to the fore often. In aggregate, I have likely spent months of my life discussing the risks and benefits of this much maligned drug. Common rat poison is made from the same ingredients as warfarin — only rats keep eating it and die days later of bleeding, while humans have the blood thinning effects modulated through frequent blood tests, called the INR. Adjusting the INR within two-three times normal results in significant stroke reduction in patients with AF.

No drug with proven benefits has received more negative press than warfarin. It is a difficult drug to administer, significant drug-dietary interactions exist, and the bleeding risk associated with inappropriately high INRs are substantial. For years now, doctors and patients alike have waited for an aspirin-like pill which can thin the blood without the need for monitoring, or the worry of drug/dietary interactions.

Patients have asked, so here is a brief introduction to dabigatran –marketed in Europe as Pradaxa. Dabigatran is likely to be the first warfarin substitute. It is an orally administered, twice daily blood thinner that works like warfarin, only further downstream in the blood clotting cascade. As an inhibitor of thrombin, it slows the blood clotting process. Stroke is the one of the major complications of AF, therefore, prevention of clots in the left atrium of the heart during atrial fibrillation is a central tenet of therapy.

The RE-LY study, published in September 2009 in the NEJM, showed dabigatran superior to warfarin in stroke prevention, but most importantly, there were significantly fewer bleeding episodes. It is beyond the scope of this piece to discuss the statistical details, but suffice to say, this 18,000 patient multi-center prospective study unequivocally demonstrated dabigatran’s superiority to warfarin in the treatment of AF. The science was exemplary.

Other practical advantages of dabigatran over warfarin include; blood thinning without the need for blood tests, it is well tolerated with minimal adverse effects (including no significant liver toxicity), it has minimal drug interactions, and no significant dietary interactions.

Dabigatran is the property of the privately held German pharmaceutical company Boehringer Ingelheim. Although approved in Europe, dabigatran is not yet approved in the US. It was submitted to the FDA in December with approval expected later this year.

Finally, a substitute for warfarin is close. Yes, the drug is considered both superior in efficacy and safer than warfarin by most experts, and so, in a “perfect” system of healthcare, it should be readily available to all. It is best for the patient, right?

However, consider that in the socialized medical system of Europe, dabigatran costs nearly ten times as much as warfarin. In the US healthcare system, it seems certain dabigatran will cost much more. Patients will have before their eyes a clearly superior drug with less bleeding risk –a substitute for rat poison.

Great news one would think, but consider the upcoming choice of costs versus efficacy and safety. Dabigatran will cost many times that of warfarin, likely in the hundreds per month. Will insurance companies be cajoled into paying? Will patients pay extra? How about Medicare? Government tells us Medicare costs are to be reduced. Surely not by paying 10 times more for such a commonly used drug as warfarin. The upcoming adjudication of this superior, but expensive new drug will make for an interesting and instructive story.

Maybe the Boehringer Ingelheim people will price the drug reasonably in hopes of developing brand loyalty, and to strengthen their competitiveness against the newer direct thrombin inhibitors that are sure to come. For just a fantasy moment, let’s say dabigatran cost only 2-5 times more than warfarin. It follows that many more patients would switch, and what profit is lost on margin will be made up in volume.

But, no, this will never happen –forget I even suggested it.

John Mandrola is a cardiologist who blogs at Dr John M.

ADVERTISEMENT

Submit a guest post and be heard.

Prev

Health blog posts of the week, April 9-16, 2010

April 18, 2010 Kevin 0
…
Next

Health reform needed a moderate third party

April 19, 2010 Kevin 3
…

Tagged as: Cardiology, Medications, Specialist

Post navigation

< Previous Post
Health blog posts of the week, April 9-16, 2010
Next Post >
Health reform needed a moderate third party

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by John Mandrola, MD

  • What we can learn about weight loss from Al Sharpton

    John Mandrola, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Don’t be foolish enough to think you control outcomes

    John Mandrola, MD
  • a desk with keyboard and ipad with the kevinmd logo

    The problem with Obamacare is that it doesn’t do enough

    John Mandrola, MD

More in Meds

  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
  • Recent Posts

    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why young doctors in South Korea feel broken before they even begin

      Anonymous | Education
    • Measles is back: Why vaccination is more vital than ever

      American College of Physicians | Conditions
    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 8 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
  • Recent Posts

    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why young doctors in South Korea feel broken before they even begin

      Anonymous | Education
    • Measles is back: Why vaccination is more vital than ever

      American College of Physicians | Conditions
    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Dabigatran is superior to warfarin, but at what cost?
8 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...